Recently, following the publication of randomized clinical trials demonstrating the efficacy of AIs in the treatment of BC [17–19], additional studies have reported associations between CYP19A1 polymorphisms and clinical response (CR) and/or adverse effects (AEs) in BC patients treated with AIs [20, 21]. This evidence concerns the gene CYP19A1 and breast cancer.